Document is current

Article History

Received: 19 August 2024

Accepted: 3 May 2025

First Online: 12 May 2025

Declarations

:

: NN: Chugai, Pfzer, Eisai, Mochida Institutional, Daiichi Sankyo and Novartis; MT: Chugai, Taiho, Takeda, JBCRG assoc., Pfzer, KBCRN assoc., Eisai, Eli-Lilly and companies, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi, GL Science, Sanwa Shurui, and Zene; SS: Taiho, Eisai, Chugai, Takeda, MSD, Astra Zeneca, and Daiichi Sankyo. Consulting fees: HK: EPS corporation; HK: Chugai Pharmaceuticals; NN: Chugai, Eli Lilly, MSD, Daiichi-Sankyo, AstraZeneca and Pfzer; YS: Pfzer, Astra Zeneca, Daiichi Sankyo, Eisai, Eli Lily, Chugai, MSD and Nihon Kayaku; MM: Chugai, AstraZeneca, Eli Lilly, Pfzer, MSD, Taiho, Daiichi Sankyo and Eisai; NH: Eli Lilly, Astrazeneca, taiho, Eizai, ExactScience,Daiichi Sankyo, Novartis, Pfzer, and Chugai; MT: Chugai, Takeda, Pfzer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly and companies, Daiichi-Sankyo, MSD, Exact Science, Novartis, Shimadzu, Yakult, Nippon Kayaku, Devicore medical Japan, and Sysmex; SS: Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfzer, Taiho, Ono, and Nipponkayaku. Participation on a Data Safety Monitoring Board or Advisory Board: MT: Daiichi-Sankyo, Eli Lilly and companies, Bertis, Terumo, and Kansai Medical Ne; SS: Chugai/Roche, Astra Zeneca, Eli Lilly, Pfzer, Kyowa Kirin, Daiichi Sankyo, and MSD. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: SS: JBCRG, JBCS, JSMO, and BIG.Other fnancial or non-fnancial interests: HK: Afliation to HQA, a social collaborative department supported by National CLinlical Database, Johnson & Johnson KK, Nipro corporation and Intuitive Surgical Sarl; MT: British Journal of Cancer, Scientifc Reports, Breast Cancer Research and Treatment, and Cancer Science. HK reports receiving consultation fee from EPS Corporation, speaker fee from Chugai Pharmaceutical Co., Ltd, and a research grant on an unrelated subject from Amgen K.K. HK is affiliated with the Department of Healthcare Quality Assessment at the University of Tokyo, a social collaboration department supported by the National Clinical Database, Johnson & Johnson K.K., Nipro corporation, and Intuitive Surgical Sàrl. Shigehira Saji is an editorial board member of Cancer Science.

: The protocol of the study was approved by the Ethics Committee of the Institutional Review Board (No. 2021-1-852).

: Not Applicable.

: Not Applicable.

: Not Applicable.